Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000291337 | SCV000338496 | pathogenic | not provided | 2016-01-19 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV000291337 | SCV002019497 | pathogenic | not provided | 2020-11-16 | criteria provided, single submitter | clinical testing | |
Ce |
RCV000291337 | SCV002063143 | likely pathogenic | not provided | 2021-10-01 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV003475908 | SCV004204103 | likely pathogenic | Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A2 | 2023-08-16 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV003765630 | SCV004610187 | pathogenic | Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A2; Muscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B2; Autosomal recessive limb-girdle muscular dystrophy type 2N | 2023-07-29 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 285471). This variant has not been reported in the literature in individuals affected with POMT2-related conditions. This variant is present in population databases (no rsID available, gnomAD 0.004%). This sequence change creates a premature translational stop signal (p.Asn553Lysfs*10) in the POMT2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in POMT2 are known to be pathogenic (PMID: 15894594). |